Overall, our findings identify EBBP as a novel suppressor of ferroptosis in anthracycline‐induced cardiotoxicity via the PERK‐mediated ISR, thereby underscoring its therapeutic potential for preventing anthracycline‐induced cardiomyopathy. Here, EIF2AK3 is linked to cardiomyopathy.